Q1 Earnings Estimate for SBC Medical Group Issued By Sidoti

SBC Medical Group Holdings Incorporated (NASDAQ:SBC) – Sidoti decreased their Q1 2026 earnings per share (EPS) estimates for shares of SBC Medical Group in a research note issued to investors on Wednesday, April 1st. Sidoti analyst A. Shah now forecasts that the company will post earnings per share of $0.10 for the quarter, down from their previous forecast of $0.11. The consensus estimate for SBC Medical Group’s current full-year earnings is $5.02 per share. Sidoti also issued estimates for SBC Medical Group’s Q2 2026 earnings at $0.12 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.13 EPS, FY2026 earnings at $0.47 EPS, Q1 2027 earnings at $0.12 EPS, Q2 2027 earnings at $0.13 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.13 EPS and FY2027 earnings at $0.52 EPS.

Other research analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of SBC Medical Group in a report on Friday, March 27th. BTIG Research initiated coverage on SBC Medical Group in a report on Friday, March 6th. They set a “buy” rating and a $8.00 price objective for the company. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.50.

SBC Medical Group Price Performance

SBC opened at $4.47 on Thursday. The stock has a fifty day moving average of $4.12 and a 200-day moving average of $4.04. The firm has a market capitalization of $458.53 million, a P/E ratio of 9.12 and a beta of 0.99. SBC Medical Group has a 12-month low of $2.97 and a 12-month high of $5.75. The company has a quick ratio of 5.06, a current ratio of 3.78 and a debt-to-equity ratio of 0.13.

SBC Medical Group (NASDAQ:SBC) last announced its earnings results on Friday, March 27th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. SBC Medical Group had a return on equity of 20.76% and a net margin of 29.37%.The company had revenue of $39.57 million for the quarter, compared to analyst estimates of $45.19 million.

Insider Buying and Selling at SBC Medical Group

In related news, CEO Yoshiyuki Aikawa sold 4,422,900 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.12, for a total value of $9,376,548.00. Following the transaction, the chief executive officer directly owned 861,600 shares of the company’s stock, valued at approximately $1,826,592. This trade represents a 83.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 89.47% of the company’s stock.

Hedge Funds Weigh In On SBC Medical Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SBC. Russell Investments Group Ltd. lifted its stake in shares of SBC Medical Group by 292.0% in the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock worth $51,000 after buying an additional 8,771 shares during the last quarter. Barclays PLC boosted its stake in SBC Medical Group by 123.7% during the 4th quarter. Barclays PLC now owns 17,779 shares of the company’s stock valued at $77,000 after purchasing an additional 9,831 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of SBC Medical Group by 91.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 27,341 shares of the company’s stock worth $118,000 after buying an additional 13,074 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of SBC Medical Group by 195.1% in the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock valued at $54,000 after acquiring an additional 8,348 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of SBC Medical Group in the fourth quarter worth $53,000. Institutional investors and hedge funds own 60.82% of the company’s stock.

SBC Medical Group News Roundup

Here are the key news stories impacting SBC Medical Group this week:

• Negative Sentiment: Sidoti trimmed several quarterly EPS forecasts (typically by $0.01–$0.02 per quarter) for 2026–2027 and lowered full‑year estimates — FY2026 to $0.47 from $0.50 and FY2027 to $0.52 from $0.59. This reduces near‑term earnings expectations and could pressure the stock if other analysts follow suit. Sidoti research note

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.